Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Antibody Drug Conjugates Market, by Application
1.4.2 Europe Antibody Drug Conjugates Market, by Technology
1.4.3 Europe Antibody Drug Conjugates Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition & mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, May – 2022, Mar) Leading Players
Chapter 4. Europe Antibody Drug Conjugates Market by Application
4.1 Europe Breast Cancer Market by Country
4.2 Europe Blood Cancer Market by Country
4.3 Europe Urothelial Cancer & Bladder Cancer Market by Country
4.4 Europe Others Market by Country
Chapter 5. Europe Antibody Drug Conjugates Market by Technology
5.1 Europe Cleavable Linker Market by Country
5.2 Europe Non-Cleavable Linker Market by Country
5.3 Europe Others Market by Country
Chapter 6. Europe Antibody Drug Conjugates Market by Country
6.1 Germany Antibody Drug Conjugates Market
6.1.1 Germany Antibody Drug Conjugates Market by Application
6.1.2 Germany Antibody Drug Conjugates Market by Technology
6.2 UK Antibody Drug Conjugates Market
6.2.1 UK Antibody Drug Conjugates Market by Application
6.2.2 UK Antibody Drug Conjugates Market by Technology
6.3 France Antibody Drug Conjugates Market
6.3.1 France Antibody Drug Conjugates Market by Application
6.3.2 France Antibody Drug Conjugates Market by Technology
6.4 Russia Antibody Drug Conjugates Market
6.4.1 Russia Antibody Drug Conjugates Market by Application
6.4.2 Russia Antibody Drug Conjugates Market by Technology
6.5 Spain Antibody Drug Conjugates Market
6.5.1 Spain Antibody Drug Conjugates Market by Application
6.5.2 Spain Antibody Drug Conjugates Market by Technology
6.6 Italy Antibody Drug Conjugates Market
6.6.1 Italy Antibody Drug Conjugates Market by Application
6.6.2 Italy Antibody Drug Conjugates Market by Technology
6.7 Rest of Europe Antibody Drug Conjugates Market
6.7.1 Rest of Europe Antibody Drug Conjugates Market by Application
6.7.2 Rest of Europe Antibody Drug Conjugates Market by Technology
Chapter 7. Company Profiles
7.1 Takeda Pharmaceutical Company Limited
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expense
7.1.1 Recent strategies and developments:
7.1.1.1 Partnerships, Collaborations, and Agreements:
7.1.1.2 Acquisitions and Mergers:
7.2 F. Hoffmann-La Roche Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 AstraZeneca PLC
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 GlaxoSmithKline PLC
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations and Agreements:
7.6 Astellas Pharma, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.6.5.2 Approvals and Trials:
7.7 Gilead Sciences, Inc.
7.7.1 Company overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.7.4 Recent strategies and developments:
7.7.4.1 Acquisitions and Mergers:
7.7.4.2 Partnerships, Collaborations and Agreements:
7.8 Seagen, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expenses
7.8.4 Recent strategies and developments:
7.8.4.1 Partnerships, Collaborations, and Agreements:
7.9 ADC Therapeutics SA
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expenses
7.9.4 Recent strategies and developments:
7.9.4.1 Partnerships, Collaborations, and Agreements:
7.9.4.2 Approvals and Trials:
7.10. Daiichi Sankyo Company, Limited
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Research & Development Expense
7.10.4 Recent strategies and developments:
7.10.4.1 Partnerships, Collaborations, and Agreements:
Unique Offerings 